=> d l1
L1 HAS NO ANSWERS
L1 STR



VPA 22-16/18/19 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1 19 13
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 15:10:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 32191 TO ITERATE

100.0% PROCESSED 32191 ITERATIONS 305 ANSWERS
SEARCH TIME: 00.00.01

L3 305 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	156.68	156.89

FILE 'CAPLUS' ENTERED AT 15:10:42 ON 23 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Dec 2004 VOL 141 ISS 26
FILE LAST UPDATED: 22 Dec 2004 (20041222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 5 L3

=> d bib abs 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:344622 CAPLUS
DN 140:357212
TI Preparation of substituted anilinic piperidines as MCH selective antagonists
IN Marzabadi, Mohammad R.; Wetzel, John; Deleon, John E.; Jiang, Yu; Chen, Chien-An; Lu, Kai
PA Synaptic Pharmaceutical Corporation, USA
SO U.S., 394 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6727264	B1	20040427	US 2002-188434	20020703
PRAI	US 2001-303091P	P	20010705		
	US 2002-346997P	P	20020109		

OS MARPAT 140:357212
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I (R1 = H, alkyl, aryl, etc.; R2 = alkyl, cyclopropyl; R3 = (un)substituted (hetero)aryl; A = H, F, Cl, Br, CN, etc.; X = O, NH; n = 0-5), II (W = III, IV (wherein R1 = H, Me, Et; X = O, NR3, CO, a bond; Y = H, (hetero)aryl; R3 = H, (hetero)aryl); R2 and A as above)] which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors, were prepared Thus, reacting 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide (preparation given) with 4-chloro-3',4'-dimethylbutyrophenone in the presence of K2CO3 and NaI in DMF afforded 80% V which showed Ki of 3.9 nM in cloned rat MCH1 binding assay.
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:162444 CAPLUS
DN 140:212060
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof and preparation of 4-phenylpiperidine derivatives as human MCH1 receptor antagonists
IN Salon, John A.; Laz, Thomas M.; Nagorny, Raisa; Wilson, Amy E.; Craig, Douglas A.
PA USA
SO U.S. Pat. Appl. Publ., 180 pp., Cont.-in-part of U.S. Ser. No. 899,732.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004038855	A1	20040226	US 2003-341751	20030114

WO 2000039279 A2 20000706 WO 1999-US31169 19991230
WO 2000039279 A3 20001102
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2003082623 A1 20030501 US 2001-899732 20010705
WO 2004064774 A2 20040805 WO 2004-US724 20040114
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI
PRAI WO 1999-US31169 A2 19991230
US 2000-610635 B2 20000705
US 2001-899732 A2 20010705
US 2003-341751 A 20030114
GI



I

AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compds. to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence or overactive bladder. Various 4-phenylpiperidine derivs., e.g (I), were synthesized and tested as human MCH1 receptor antagonists.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:42108 CAPLUS
DN 138:106601
TI Preparation of substituted anilinic piperidines as MCH selective antagonists
IN Marzabadi, Mohammad R.; Wetzel, John; Deleon, John E.; Jiang, Yu
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 771 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004027	A1	20030116	WO 2002-US21063	20020703
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1411942	A1	20040428	EP 2002-746843	20020703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002010869	A	20040629	BR 2002-10869	20020703
	JP 2004536104	T2	20041202	JP 2003-510038	20020703
	US 2004073036	A1	20040415	US 2003-345063	20030114
	US 2004186103	A1	20040923	US 2004-753057	20040106
PRAI	US 2001-899794	A	20010705		
	US 2002-42582	A	20020109		
	WO 2002-US21063	W	20020703		
	US 2003-345063	A2	20030114		

OS MARPAT 138:106601
GI



I



II

AB The title compds. [I (R1 = H, alkyl, aryl, etc.; R2 = alkyl, cyclopropyl; R3 = (un)substituted (hetero)aryl; A = H, F, Cl, Br, CN, etc.; X = O, NH; n = 0-5), II (R1 = (un)substituted (hetero)aryl; R2, A, n as above), etc.] which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors, were prepared and formulated. Thus, reacting 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide (preparation given) with 4-chloro-3',4'-dimethylbutyrophenone in the presence of K2CO3 and NaI in DMF afforded 80% II [R1 = R1 = 3,4-Me2C6H3; R2 = iso-Pr; A = H; n = 2] which showed Ki of 3.9 nM in cloned rat MCH1 binding assay.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:793613 CAPLUS
DN 137:310934
TI Preparation of piperidinyl-, piperazinylcarboxamides as lipid lowering agents
IN Meerpoel, Lieven; Viellevoye, Marcel
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002081460	A1	20021017	WO 2002-EP3491	20020327
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2441398	AA	20021017	CA 2002-2441398	20020327
	EE 200300488	A	20031215	EE 2003-488	20020327
	EP 1379515	A1	20040114	EP 2002-722278	20020327
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002008688	A	20040309	BR 2002-8688	20020327
	NZ 528445	A	20040326	NZ 2002-528445	20020327
	JP 2004525176	T2	20040819	JP 2002-579448	20020327
	NO 2003004474	A	20031204	NO 2003-4474	20031006
PRAI	EP 2001-201270	A	20010406		
	WO 2002-EP3491	W	20020327		

OS MARPAT 137:310934
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [r,s,q = 1-3; p = 0-1; R1 = H, alkyl, alkyloxy, halo, hydroxy, mercapto, cyano, nitro, etc.; R2 = H, alkyl, alkyloxy, halo, CF3; R3 = H, alkyl; R4 = alkyl, alkyloxy, halo, CF3; Z = e.g., -X1(R5)-(CH2)n-X2(R6)-; n = 2-4; R5-6 = H, alkyl, aryl; X1-2 = CH, N, sp2

hybridized carbon, etc.; A = bond, alkanediyl, etc.; B = e.g., R8-OCO-alkanediyl-Y-; Y = O, amino, etc.; R8 = alk(en/yn)yl, etc.] were prepared For instance, N-[4-(1-piperazinyl)phenyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide (preparation given) was reacted with α-chlorobenzeneacetic acid 2-methoxy-2-oxoethyl ester (preparation given, DMF, Na2CO3) to afford, after purification, II, m.p. 106°. II inhibited microsomal triglyceride transfer protein (MTP) activity with pIC50 = 6.591. I are useful for the treatment of hyperlipidemia, obesity and type II diabetes.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:71877 CAPLUS
DN 136:134783
TI Preparation of piperazine(or piperidine)-1-carboxamides as CCR5 modulators
IN Bondinell, William E.; Neeb, Michael J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002005819	A1	20020124	WO 2001-US22529	20010713
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001080599	A5	20020130	AU 2001-80599	20010713
	EP 1313477	A1	20030528	EP 2001-958995	20010713
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004038982	A1	20040226	US 2003-343880	20030205
PRAI	US 2000-218509P	P	20000715		
	WO 2001-US22529	W	20010713		

OS MARPAT 136:134783
GI



I



II

AB The title compds. [I; the basic N atom in moiety E may be optionally quaternized with alkyl or optionally present as the N-oxide; A = (un)substituted (hetero)aryl or (hetero)aryl fused to a saturated or partly unsatd. 5-7 membered ring; D = a bond, CO, SO2, etc.; E1G = NC(R26)2, NC(R26)2C(R26)2, CR27C(R26)2, C:CR26; R26 = H, alkyl; R27 = H, CN, NO2, etc.; R = H, alkyl, O; J = CO, SO2; L = NR30, O, C(R30)2; R30 = H, alkyl; E = 3-(2-diisopropylamino)ethoxy-4-methoxyphenyl, etc.] which are modulators, agonists or antagonists, of the CCR5 receptor, and therefore are useful in the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, were prepared Thus, treating 4-phenyl-1,2,3,6-tetrahydropyridine.HCl with triphosgene in the presence of Et3N in CH2Cl2 followed by addition of 3-(2-diisopropylamino)ethoxy-4-methoxyaniline afforded II. The compds. I showed CCR5 receptor modulator activity having IC50 values in the range of 0.0001-100 μM. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT